ZFP64 Antibody
Description
Introduction
ZFP64 (Zinc Finger Protein 64) is a transcription factor belonging to the Krüppel C2H2-type zinc finger family. Its antibody, ZFP64 Antibody, is a research tool used to detect and study the protein’s expression, localization, and functional roles in immune responses and cancer progression. The antibody is widely utilized in immunohistochemistry (IHC), Western blot (WB), and immunofluorescence (IF) assays to investigate ZFP64’s involvement in signaling pathways and disease mechanisms.
Properties of ZFP64 Antibody
Immunohistochemistry (IHC)
ZFP64 antibody is used to analyze tissue samples for ZFP64 expression. For example, in gallbladder cancer (GBC), high ZFP64 levels correlate with poor prognosis and metastatic traits . Specific protocols recommend dilutions of 1:200–1:500 for paraffin-embedded sections .
Western Blot (WB)
WB applications confirm ZFP64’s molecular weight (~69–71 kDa) and validate knockdown/knockout experiments. Proteintech’s 17187-1-AP antibody is commonly used for this purpose .
Immunofluorescence (IF)
IF assays localize ZFP64 in cellular compartments. Studies using ab204610 revealed nuclear enrichment of ZFP64 in U-2 OS cells, consistent with its transcriptional regulation role .
Role in Innate Immunity
ZFP64 enhances Toll-like receptor (TLR) signaling by associating with NF-κB p65, promoting proinflammatory cytokine and type I interferon production in macrophages . This mechanism is critical for pathogen recognition and immune activation.
Cancer Progression
ZFP64 overexpression drives aggressive phenotypes in cancers, including:
-
Gallbladder Cancer (GBC): Promotes proliferation, anti-apoptosis, and epithelial-to-mesenchymal transition (EMT) .
-
Leukemia: Maintains MLL fusion protein expression, essential for leukemia progression .
-
Breast Cancer: Linked to glycolysis-mediated stem-cell-like properties .
Therapeutic Implications
Targeting the ZFP64/GAL-1 axis in gastric cancer (GC) enhances chemotherapy efficacy, as demonstrated by nab-paclitaxel + GAL-1 inhibitor combination therapy .
